SCHEMBL178563

SCHEMBL178563

Cc1ccc(C(=O)NC2CC2)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
MAPK14 Q16539 5/20 0.57
CNR2 P34972 2/20 0.55
POLB P06746 2/20 0.55
MAPT P10636 2/20 0.55
TP53 P04637 1/20 0.55
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 1/20 0.52
HTT P42858 1/20 0.52
EPHX2 P34913 1/20 0.52
MAPK11 Q15759 3/20 0.52
HSPB1 P04792 1/20 0.52
CYP2C9 P11712 1/20 0.52
ADRA2A P08913 1/20 0.52
HRH1 P35367 1/20 0.52
HTR2B P41595 1/20 0.52
MCHR1 Q99705 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12459688 0.90 MEN1 (0.61) MEN1KMT2ACNR2POLBMAPT
SCHEMBL14817942 0.88 MEN1 (0.56) MEN1KMT2AMAPK14CNR2POLB
SCHEMBL14817916 0.88 MEN1 (0.56) MEN1KMT2AMAPK14CNR2POLB
SCHEMBL14568525 0.87 MEN1 (0.54) MEN1KMT2AMAPK14CNR2POLB
SCHEMBL14818044 0.85 MEN1 (0.56) MEN1KMT2ACNR2POLBMAPT
SCHEMBL10282601 0.85 GLA (0.64) MEN1KMT2AMAPK14CNR2NPC1
SCHEMBL1854917 0.83 CRHR1 (0.71) MEN1KMT2AMAPK14MAPK11HSPB1
SCHEMBL1854916 0.83 CRHR1 (0.71) MEN1KMT2AMAPK14MAPK11HSPB1
SCHEMBL13146407 0.83 MAPK14 (0.56) MEN1KMT2AMAPK14CNR2NPC1
SCHEMBL25548 0.82 MAPK14 (0.58) KMT2AMAPK14CNR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
US-7208629-B2 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-04-24 US disclosed
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435936-A1 5'-CARBAMOYL-1,1-BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032972-A1 5’-CARBAMOYL-1,1-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 MEN1 3210/4885KMT2A 2603/4885MAPK14 1421/4885
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors MAPK4, GRK4, NR4A1 MEN1 3787/4885KMT2A 711/4885MAPK14 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.